Related Experiment Video
Updated: Nov 12, 2025

CRISPR-Mediated Reorganization of Chromatin Loop Structure
Published on: September 14, 2018
Epigenetic modulation reveals differentiation state specificity of oncogene addiction
Mehwish Khaliq1, Mohan Manikkam1, Elisabeth D Martinez2,3
1Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
Abstract:
Hyperactivation of the MAPK signaling pathway motivates the clinical use of MAPK inhibitors for BRAF-mutant melanomas. Heterogeneity in differentiation state due to epigenetic plasticity, however, results in cell-to-cell variability in the state of MAPK dependency, diminishing the efficacy of MAPK inhibitors. To identify key regulators of such variability, we screen 276 epigenetic-modifying compounds, individually or combined with MAPK inhibitors, across genetically diverse and isogenic populations of melanoma cells. Following single-cell analysis and multivariate modeling, we identify three classes of epigenetic inhibitors that target distinct epigenetic states associated with either one of the lysine-specific histone demethylases Kdm1a or Kdm4b, or BET bromodomain proteins. While melanocytes remain insensitive, the anti-tumor efficacy of each inhibitor is predicted based on melanoma cells' differentiation state and MAPK activity. Our systems pharmacology approach highlights a path toward identifying actionable epigenetic factors that extend the BRAF oncogene addiction paradigm on the basis of tumor cell differentiation state.
Insights
Scientists screened epigenetic compounds to overcome resistance to MAPK inhibitors in melanoma. They identified epigenetic drug classes targeting specific cell states, improving anti-tumor efficacy based on differentiation and MAPK activity.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- The MAPK signaling pathway is a key target for BRAF-mutant melanoma treatment.
- Epigenetic plasticity causes cell variability, reducing MAPK inhibitor efficacy.
- Identifying regulators of this variability is crucial for improving melanoma therapy.
Purpose of the Study:
- To screen epigenetic compounds for their ability to modulate MAPK inhibitor efficacy in melanoma.
- To identify specific epigenetic targets and drug classes that overcome treatment resistance.
- To correlate anti-tumor efficacy with melanoma cell differentiation state and MAPK activity.
Main Methods:
- Screening of 276 epigenetic-modifying compounds alone and with MAPK inhibitors.
- Utilizing genetically diverse and isogenic melanoma cell populations.
- Employing single-cell analysis and multivariate modeling.
Main Results:
- Identified three classes of epigenetic inhibitors targeting KDM1A, KDM4B, or BET bromodomain proteins.
- Demonstrated that anti-tumor efficacy is predictable based on melanoma cell differentiation and MAPK activity.
- Showed melanocytes are insensitive to these epigenetic inhibitors.
Conclusions:
- Epigenetic drug screening can identify novel therapeutic strategies for melanoma.
- Targeting specific epigenetic states offers a way to overcome MAPK inhibitor resistance.
- Tumor cell differentiation state is a key factor in predicting response to epigenetic therapies.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Combinatorial Gene Control
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...

